Table 3. Characteristics of cohort studies implementing pharmacist-led symptom management interventions for atrial fibrillation.
Author (study name), year, country Study setting (n) Intervention/controlaSample sizebAge (median [IQR], or mean ± SD)cProportion of females, n (%) Description of intervention and control (where applicable) Main outcomes of intervention
Labreck, 2021, USA49 Antiarrhythmic clinic (1) a12/9
c3 (25%)/4 (44.5%)
Pharmacy-led outpatient clinic using the AliveCor Kardia Mobile ECG to deliver sotalol loading (electrophysiologist oversight) vs. inpatient sotalol loading (control) Inpatients administered 120mg twice daily, 88.3% outpatients received this dose (three received different doses at electrophysiologist discretion (n=2), or because of prolonged baseline QT interval (n=1)
Finks, 2011, USA48 Hospital (1) a36
b75 ± 8.9 dose appropriate or accepted dose adjustment, 78 ± 7.6 partial dose adjustment or no adjustment
Pharmacist assessment of sotalol prescribing for atrial fibrillation patients according to renal function, physician prescribing recommendations made when appropriate Pharmacist recommendation of drug discontinuation/ dose amendment in 32/36, accepted for 12/32 (appropriate therapy) but not for 20/32 (inappropriate therapy), no effect on all-cause hospital re-admission rates at six months for patients on appropriate therapy (31% vs. 55%, p=0.095)
ECG, electrocardiogram
available as abstract only
not reported